Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 0.75 |
| ▸ | PIK3R1 | P27986 | 12/20 | 0.75 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.75 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.75 |
| ▸ | RAF1 | P04049 | 1/20 | 0.75 |
| ▸ | MTOR | P42345 | 7/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21929464 | 0.92 | PIK3CA (0.75) | PIK3CAPIK3R1PIK3CDPIK3CBRAF1 | |
| SCHEMBL21929462 | 0.92 | PIK3CA (0.77) | PIK3CAPIK3R1PIK3CDPIK3CBRAF1 | |
| SCHEMBL22006217 | 0.91 | PIK3CA (0.76) | PIK3CAPIK3R1PIK3CDPIK3CBRAF1 | |
| SCHEMBL21929467 | 0.90 | PIK3CA (0.65) | PIK3CAPIK3R1PIK3CDPIK3CBRAF1 | |
| SCHEMBL21929585 | 0.90 | PIK3CA (0.65) | PIK3CAPIK3R1PIK3CDPIK3CBRAF1 | |
| SCHEMBL23434892 | 0.89 | PIK3CA (0.60) | PIK3CAPIK3R1PIK3CDPIK3CBRAF1 | |
| SCHEMBL21929583 | 0.89 | PIK3CA (0.77) | PIK3CAPIK3R1PIK3CDPIK3CBRAF1 | |
| SCHEMBL21929465 | 0.89 | PIK3CA (0.63) | PIK3CAPIK3R1PIK3CDPIK3CBRAF1 | |
| SCHEMBL21929596 | 0.87 | PIK3CA (0.66) | PIK3CAPIK3R1PIK3CDPIK3CBRAF1 | |
| SCHEMBL21929461 | 0.86 | PIK3CA (0.73) | PIK3CAPIK3R1PIK3CDPIK3CBRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11214572-B2 | 7-site substituted pyrrole triazine compounds or pharmaceutically acceptable salts thereof, and preparation method thereof and uses thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2022-01-04 | — | — | US | disclosed |
| EP-3643717-B1 | 7-SUBSTITUTED PYRROLE TRIAZINE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PREPARATION METHOD THEREFOR AND USES THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2021-06-02 | — | — | EP | disclosed |
| US-20200157110-A1 | 7-SITE SUBSTITUTED PYRROLE TRIAZINE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PREPARATION METHOD THEREOF AND USES THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-05-21 | — | — | US | disclosed |
| EP-3643717-A1 | 7-SITE SUBSTITUTED PYRROLE TRIAZINE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PREPARATION METHOD THEREFOR AND USES THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2020-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11214572-B2 | 7-site substituted pyrrole triazine compounds or pharmaceutically acceptable salts thereof, and preparation method thereof and uses thereof | PIK3R5, JAK2, PIK3C3 | PIK3CA 9/4885PIK3R1 6/4885PIK3CD 4/4885 |
| US-20200157110-A1 | 7-SITE SUBSTITUTED PYRROLE TRIAZINE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PREPARATION METHOD THEREOF AND USES THEREOF | PIK3R5, JAK2, PIK3C3 | PIK3CA 9/4885PIK3R1 6/4885PIK3CD 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.